Last reviewed · How we verify
NCT03195231
Wuling Powder for the Treatment and Underlying Mechanism of Depressive Symptoms in Patients With Parkinson's Disease
Phase 4 trial testing Wuling Powder in Antidepressive Agents in 120 participants. Status unknown.
15 December 2019
Quick facts
| Lead sponsor | Beijing Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 25 June 2017 |
| Primary completion | 15 December 2019 |
| Estimated completion | 15 January 2020 |
Drugs / interventions tested
- Wuling Powder
- Placebo
Conditions studied
- Antidepressive Agents — all drugs for Antidepressive Agents →
Sponsor
Beijing Hospital
Who can join
40 and older, any sex, with Antidepressive Agents. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Depression is one of the most important nonmotor features of idiopathic PD（Parkinson's disease ）which may not just interfere with the motor symptoms of PD but can also cause immense personal suffering as well as decreased quality of life with increased disability and caregiver burden. However,there is little hard evidence to guide clinical treatment. Although some newer dopamine agonists also have antidepressive effect, the use of tricyclic or nontricyclic antidepressants is frequently required.However, the side-effects of these agents may also worsen some preexisting nonmotor problems in PD. Wuling powder is a Chinese medicine which is made by cultivating Xylariasp mycelium using submerged fermentation technology. Xylariasp is the fungus sclerotia which grow in termite nests. Wuling powder is mainly used to soothe nerves and anti-insomnia in clinical. The antidepressant effect of Wuling powder has been confirmed in clinical, but not in the patients of Parkinson's disease. Therefore, the investigators design a randomized, double-blind, placebo-controlled study to evaluate the antidepressant effect of Wuling powder in PD patients and its underlying mechanism.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03195231
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Wuling Powder
Trials testing the same drug.
- NCT04812236 — Clinical Study on Wuling Powder in Treating Metabolic Syndrome of Spleen Deficiency and Dampness · Phase 4 · unknown
Other Beijing Hospital trials
Trials by the same sponsor.
- NCT07523724 — Screening and Management of Adults With Asthma and Allergic Diseases · NA · not yet recruiting
- NCT07398430 — Metabolic Characteristics and Prognostic Model of Acute Coronary Syndrome Complicated With Obstructive Sleep Apnea · not yet recruiting
- NCT07295665 — External Validation of Ischemia and Hemorrhage Risk Models in Patients With Coronary Heart Disease · not yet recruiting
- NCT07143851 — Multi-modal Intelligent Diagnosis System for Multiple Ophthalmic Diseases · not yet recruiting
- NCT06955819 — GUTPROH: Probiotic-Herbal Formula for Self-Reported Constipation in Community Adults · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03195231 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Hospital
- Last refreshed: 22 June 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03195231.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing